Fourpath Capital Management’s Immunovant IMVT Stock Holding History

Fourpath Capital Management’s Portfolio IMVT Stock Details IMVT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-1	Closed	-$29	–	493
2024 Q3	$29	Buy	+1	New	+$29	﹤0.01%	772

Other funds holding IMVT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

AGM

Alpine Global Management New York $668M AUM 20.22% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Fourpath Capital Management's IMVT Position: Q4 2024 in Review

Fourpath Capital Management sold out of Immunovant (IMVT) in Q4 2024, closing a stake of 1 share — an estimated $29 sold.

Fourpath Capital Management first reported a position in IMVT in Q3 2024 and held it in 1 quarter. The position peaked at $29 in Q3 2024. 186 funds tracked by Wall St. Rank hold IMVT as of Q4 2024.

Fourpath Capital Management reported no remaining Immunovant position as of Q4 2024 after selling out during the quarter.
Fourpath Capital Management sold 1 Immunovant share in Q4 2024, an estimated $29.
Fourpath Capital Management first reported a position in Immunovant in Q3 2024 and held it in 1 quarter.
Fourpath Capital Management's Immunovant position peaked at $29 in Q3 2024.
186 funds tracked by Wall St. Rank held Immunovant as of Q4 2024.

Based on Fourpath Capital Management's 13F filing for Q4 2024, filed 24 Jan 2025.